Metformin and rapamycin are the two repurposed prescription drugs most often floated as longevity tools, and they are frequently lumped together. They shouldn’t be. They act on overlapping but distinct pathways, the strength of evidence behind them is very different, and they carry very different risk profiles. If you’re weighing metformin vs rapamycin, the single most important fact is this: in the most rigorous animal testing, rapamycin extends lifespan reliably and metformin, on its own, does not.
Here’s an honest head-to-head across mechanism, evidence, dosing, risk and who each might suit.
Mechanism: adjacent pathways, different leverage
Both drugs ultimately touch mTOR, the growth-and-nutrient-sensing pathway whose suppression is tightly linked to longevity across species — but they get there differently.
- Metformin is primarily an AMPK activator. By switching on this cellular energy sensor it improves insulin sensitivity, promotes autophagy and indirectly dampens mTOR. Its effect on mTOR is a downstream consequence, not its main action, and it is comparatively modest.
- Rapamycin is a direct inhibitor of mTOR complex 1 (mTORC1). It binds and suppresses the pathway head-on. At the intermittent, low doses used in longevity contexts, it is thought to selectively inhibit mTORC1 — which drives autophagy and suppresses the inflammatory senescence-associated secretory phenotype — while largely sparing mTORC2, the complex whose inhibition causes most of the metabolic side effects.
Put simply, metformin nudges a metabolic switch and mTOR feels it secondhand; rapamycin pulls the mTOR lever directly. For a fuller treatment of the latter, see our deep dive on rapamycin for longevity, and our companion piece on metformin and the TAME trial.
Evidence strength: this is where they diverge
This is the decisive difference. Rapamycin has produced the most robust pharmacological lifespan extension ever seen in mammals. In the US National Institute on Aging’s Interventions Testing Program (ITP) — which tests compounds across several independent labs in genetically diverse mice, a design built to weed out flukes — rapamycin extended median lifespan substantially in multiple runs and in both sexes.
Metformin’s record in the same programme is the opposite story: metformin alone did not significantly extend mouse lifespan at the dose tested. Its longevity reputation rests largely on worm studies, some less-rigorous rodent work, and human observational data that have been heavily criticised and have failed to replicate cleanly.
Crucially, neither drug has a completed human trial showing it extends lifespan or healthspan. Rapamycin’s human longevity research is early-stage safety work — a notable recent year-long study in healthy adults found weekly low-dose rapamycin was reasonably well tolerated, though it missed its primary metabolic endpoint. Metformin’s definitive test, the TAME trial, has been stalled by funding problems and has not launched at scale. So both are unproven in humans — but rapamycin enters that gap with far stronger preclinical backing.
Dosing patterns in longevity medicine
The two are used very differently off-label.
- Metformin is taken daily, typically in the 500–2,000 mg/day range familiar from diabetes care, usually with food to limit stomach upset.
- Rapamycin is used intermittently — commonly a single low weekly dose (often cited in the low single-digit-milligram range) rather than the daily high doses used for immunosuppression after organ transplant. The intermittent schedule is the whole point: it aims to capture the autophagy and anti-inflammatory benefits of hitting mTORC1 while giving the immune system time to recover between doses.
Both dosing approaches for longevity are off-label and not standardised by any regulator.
Risk profiles
Metformin is the gentler, better-understood drug. Its main downsides are gastrointestinal side effects, long-term vitamin B12 depletion and a rare risk of lactic acidosis, mostly in people with impaired kidney function. It is cheap, decades-old and widely prescribed. Its one longevity-specific catch is evidence that it can blunt muscle and fitness gains from exercise in older adults.
Rapamycin is the higher-stakes option. As an immunomodulator it raises legitimate concerns about infection risk, mouth ulcers, impaired wound healing and changes in blood lipids and glucose. The intermittent low-dose strategy is designed to minimise these, but the long-term safety of taking it for decades in healthy people simply isn’t known. It demands medical supervision and monitoring — and notably, some high-profile longevity enthusiasts have stepped back from it as the risk-benefit picture is reassessed.
Who might each suit?
This is necessarily general, not personal medical advice. Broadly:
- Metformin has its clearest rationale in people with insulin resistance, prediabetes or type 2 diabetes — the populations in which it was actually studied. In a lean, fit, insulin-sensitive person it may offer little, and could work against hard-won exercise adaptations.
- Rapamycin is favoured by those who weight the strength of the animal lifespan data heavily and are willing to accept more uncertainty and closer monitoring in exchange. It is a more aggressive intervention for people comfortable operating at the experimental edge, under a clinician’s care.
Neither is a substitute for the fundamentals — sleep, resistance and aerobic training, and metabolic health — which remain the best-evidenced longevity levers by a wide margin.
Cost, access and practicality
The two drugs also differ in how easily they fit into a longevity plan on a day-to-day level. Metformin is extraordinarily cheap, has been prescribed for decades, and is familiar to almost any clinician — a doctor asked about it is on well-trodden ground, even if the longevity use is off-label. Its side effects are generally mild and manageable, and monitoring requirements are modest.
Rapamycin is a different proposition. It is more expensive, far less familiar to most general clinicians in a longevity context, and its immunomodulatory nature means sensible use involves periodic monitoring of bloodwork and a frank conversation about infection risk and timing around vaccinations, illness or surgery. That operational burden is part of the honest cost of choosing the drug with stronger animal data: the better the preclinical evidence, the more seriously the risks deserve to be managed. Neither drug, it bears repeating, is a shortcut that offsets poor sleep, inactivity or metabolic neglect.
Frequently asked questions
Is rapamycin or metformin better for longevity?
In animal studies rapamycin has far stronger, more consistent lifespan-extension evidence, while metformin alone failed to extend lifespan in the most rigorous mouse programme. But neither has proven longevity benefits in humans, and rapamycin carries greater risk and uncertainty.
Can you take metformin and rapamycin together?
Some researchers have tested the combination in animals, but there is no established human protocol for combining them for longevity, and doing so compounds the side-effect and monitoring burden. This is firmly a decision for a qualified clinician, not a DIY stack.
Why does metformin get so much attention if the mouse data are weak?
Its appeal is practical: it’s extremely cheap, familiar and safe, with plausible mechanisms and suggestive (if confounded) human observational data. The TAME trial was designed to test whether that promise is real.
Do either of these drugs replace exercise?
No. Exercise has stronger longevity evidence than either drug, and metformin may actually blunt some of exercise’s benefits — so for active people the drug could partly work against the goal.
The takeaway
Metformin and rapamycin are not two versions of the same idea. Rapamycin is a direct, potent mTOR inhibitor with the best mammalian lifespan data of any drug and a correspondingly serious risk profile that demands supervision. Metformin is a mild, cheap, well-tolerated metabolic drug whose longevity case is genuinely shaky once you look past the headlines, and which may undercut exercise gains. If the question is which has the stronger scientific backing, rapamycin wins clearly; if the question is which is safer and better understood day to day, metformin does. What neither can claim is proof that it will lengthen a human life — and that honesty should anchor any decision about either.